# LB Pharmaceuticals Inc (LBRX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $49.34, market value $1.6 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). LB Pharmaceuticals Inc reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 4.3×**. The shares trade at 4.3× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -2.2%** (5-yr avg -19.7%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -8.4%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): 98.2%**. Earnings per share rose 98.2%.

## Financial health
- **Current ratio: 41.44** (quick 41.44). Current assets cover the next year's liabilities 41.44 times.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. LB Pharmaceuticals Inc does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (8 analysts). 8 analysts cover LB Pharmaceuticals Inc; the consensus is strong_buy, with an average price target of $53.38 (+8% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **From 52-week high: -1.6%** (269.3% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 63**. An RSI of 63 is neutral.
- **Beta (1 yr): 0.58** (volatility 63%). Beta of 0.58 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=LBRX · Page: https://foliofundamentals.com/stocks/lbrx

Not investment advice.